Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

This study looks at whether tiny molecules in the blood called microRNAs can help doctors monitor how well a child's immune system is accepting a new heart after transplant — and guide decisions about anti-rejection medication. After a heart transplant, finding the right dose of immunosuppressive drugs is critical: too little risks rejection, too much risks infection. MicroRNAs may offer a more precise way to personalize this treatment. **You may be eligible if...** - You are 18 years or younger at the time of heart transplant listing - You are between 10 and 50 days after your heart transplant - You plan to continue follow-up care at the transplant center for at least one year - Your caregiver is able and willing to follow the study requirements **You may NOT be eligible if...** - You received more than just a heart transplant (e.g., heart and kidney at the same time) - You have had a previous solid organ transplant before this heart transplant - You are still on mechanical heart support or are medically unstable after transplant - You have an active infection requiring hospitalization or treatment - You had a rejection episode before study enrollment Talk to your doctor to see if this trial is right for you.